Neximmune Inc

OTC:NEXI

NexImmune, Inc. engages in the development of novel approach to immunotheraphy designed to create therapies with curative potential for patients with cancer and other life threatening immune-mediated diseases. The company is headquartered in Gaithersburg, Maryland and currently employs 74 full-time employees. The company went IPO on 2021-02-12. The firm is engaged in developing a novel approach to immunotherapy designed to employ the body’s own T cells to generate an immune response that mimics natural biology. The firm provides Artificial Immune Modulation (AIM) which is a nanoparticle technology platform. Its AIM technology enables it to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. The AIM nanoparticles employ signaling proteins to deliver instructions to T cells directing a desired immune response. Its T cell product candidates are designed to combine the attributes of cellular with reduced potential for toxicities. The Company’s two lead programs, NEXI-001 and NEXI-002, are in Phase 1/2 clinical trials for the treatment of relapsed acute myeloid leukemia (AML) after allogeneic stem cell transplantation and multiple myeloma refractory to lines of therapy, respectively.